Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07374796 · ClinicalTrials.gov registry record
Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Breast Cancer
A clinical trial, sponsored by University of Maryland, Baltimore.
- Not yet
- Registry status
- 450
- Enrollment target
NCT07374796 is a clinical trial that has not yet begun recruiting, run by University of Maryland, Baltimore. The registered enrollment target is 450 participants.
The verdict
NCT07374796 has not yet begun recruiting, sponsored by University of Maryland, Baltimore.
- NOT YET RECRUITING
- Registry status
- 450 participants
- Enrollment target
Study Summary
The purpose of this research study is to test a new process for diagnosing breast cancer by examining changes to your DNA that can be detected from a blood test. The information we learn by doing this study could potentially help people in the future. Participants in this study will have blood samples collected, have their medical records reviewed by study personnel and fill out questionnaires at different time points during the study. Blood sample collection will occur during normal routine clinic visits. Participation in this study will last approximately 5 years.
Interventions
- OTHER Epigenetic Assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2032-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07374796
The ClinicalTrials.gov registry entry for NCT07374796 describes a study currently listed as not yet recruiting, categorized as an unspecified phase. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Epigenetic Assay is the first listed.
NCT07374796 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07374796 about?
NCT07374796 is a clinical study titled "Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Breast Cancer". The purpose of this research study is to test a new process for diagnosing breast cancer by examining changes to your DNA that can be detected from a blood test. The information we learn by doing this study could potentially help people in the future. Participants in this study will have blood samp...
What is the current status of trial NCT07374796?
This trial is currently not yet recruiting. The enrollment target is 450 participants. The study started on 2026-06-01. Estimated completion is 2032-07.
What interventions are being tested in trial NCT07374796?
The interventions under investigation include: Epigenetic Assay (OTHER).
Who is sponsoring clinical trial NCT07374796?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.